Treatment of Newly Diagnosed Peripheral T-cell Lymphoma

Inclusion Criteria: * Age range 14-70 years old; ECOG performance status 0-2. * Estimated survival time \> 6 months. * Histological confirmed Peripherial T-cell lymphoma. * Have taken no treatment. * None of chemotherapy contraindication: hemoglobin ≥ 90 g/dl, neutrophil ≥ 1.5×109/L, platelet ≥ 100×109/L, ALT and AST ≤ 2×ULN, serum bilirubin ≤ 1.5×ULN, serum creatine ≤ 1.5×upper limitation of normal (ULN), Serum Albumin ≥ 30g/L, serum plasminogen is normal. * At least one measurable lesion. * None of other serious diseases, cardiopulmonary function is normal. * Pregnancy test of women at reproductive age must be negative. * Patients could be followed up. * None of other relative treatments including the traditional Chinese medicine, immunotherapy, biotherapy except anti-bone metastasis therapy and other symptomatic treatments. * Volunteers who signed informed consent. Exclusion Criteria: * Patients with contraindications (active bleeding, ulcers, intestinal perforation, intestinal obstruction, 30 days after major surgery, hypertension uncontrollable drugs, grade III-IV cardiac insufficiency, severe liver and kidney dysfunction); * Abnormal coagulation (INR \> 1.5 or prothrombin time (PT) \> ULN + 4 seconds or APTT \> 1.5 ULN), with bleeding tendency or undergoing thrombolysis or anticoagulant therapy； * Urine routine indicates urinary protein ≥ ++, or confirmed 24-hour urine protein ≥ 1.0 g; * Disagreement on blood sample collection. * Patients allergic of any of drug in this regimen or with metabolic disorder. * Pregnant or lactating women. * Serious medical illness likely to interfere with participation. * Serious infection. * Primitive or secondary tumors of central nervous system. * Chemotherapy or radiotherapy contraindication. * The evidence of CNS metastasis. * History of peripheral nervous disorder or dysphrenia. * Patients participating in other clinical trials. * Patients taking other antitumor drugs. * Patients estimated to be unsuitable by investigator.